Tmunity Therapeutics   Report issue

For profit Phase 1 Phase 2
Founded: Philadelphia PA United States (2015)
Status: Acquired by Kite Pharma, Inc. (2022) → now Gilead Sciences (2017)

Organization Overview

First Clinical Trial
2019
NCT04025216
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Tmunity Therapeutics

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 1)

Fallopian Tube Neoplasms (Phase 1)

Multiple Myeloma (Phase 1)

Neoplasms, Plasma Cell (Phase 1)

Prostatic Neoplasms (Phase 1)

Triple Negative Breast Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 5
  • # of Trial APIs: 7